Myelosuppression grading of chemotherapies for hematologic malignancies to facilitate communication between medical and dental staff: lessons from two cases experienced odontogenic septicemia

BMC Oral Health

Takahide Komori²  Hiroshi Matsuoka¹  Atsuo Okamura¹  Kimikazu Yakushijin¹  Yumiko Inui¹  Shungo Furudoi²  Junya Kusumoto²  Yasuyuki Shibuya²  Masaya Akashi² 

[1] Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan;Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

关键词: Odontogenic septicemia;    Myelosuppression grading;    Tooth extraction;    Chemotherapy;    Hematologic malignancy;   

Others  :  1125975
DOI  :  10.1186/1472-6831-13-41

 received in 2013-03-12, accepted in 2013-08-14,  发布年份 2013

【 摘 要 】

Background

Odontogenic diseases can be a risk factor for life-threatening infection in patients with hematologic malignancies during chemotherapy that induces myelosuppression of variable severity. Previous studies noted the necessity of the elimination of all odontogenic foci before hematopoietic stem cell transplantation. To enable planning for the adequate dental intervention, the oral medicine team must understand the general status of patient and the intensity of the chemotherapy, which is sometimes difficult to be fully appreciated by dental staff. Therefore, a simplified grading would facilitate the sharing of information between hematologists, dentists and oral hygienists. This study aimed to introduce our myelosuppression grading of chemotherapies for hematologic malignancies and analyze the timing of occurrence of severe odontogenic infection.

Methods

37 patients having received various chemotherapies for hematologic malignancies were enrolled. The chemotherapy regimens were classified into four grades based on the persistency of myelosuppression induced by chemotherapy. Mild myelosuppressive chemotherapies were classified as grade A, moderate ones as grade B, severe ones as grade C, and chemotherapies that caused severe myelosuppression and persistent immunodeficiency (known as conditioning regimens for transplant) as grade D. The timing of occurrence of severe odontogenic infection was retrospectively investigated.

Results

Two patients (5.4%) had severe odontogenic infections after grade B or C chemotherapy. One occurred after extraction of non-salvageable teeth; the other resulted from advanced periodontitis in a tooth that could not be extracted because of thrombocytopenia. Both were de novo hematologic malignancy patients. During grade D chemotherapy, no patients had severe odontogenic infections.

Conclusions

The simplified grading introduced in this study is considered a useful tool for understanding the myelosuppressive state caused by chemotherapy and facilitating communication between medical and dental staff. During the period around the primary chemotherapy, especially for de novo hematologic malignancy patients who often received grade B to C myelosuppression chemotherapy, caution should be exercised for severe odontogenic infection by the oral medicine team, irrespective of whether invasive treatment is to be performed.

【 授权许可】

   
2013 Akashi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Epstein JB, Raber-Durlacher JE, Wilkins A, Chavarria MG, Myint H: Advances in hematologic stem cell transplant: an update for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 107:301-312.
• [2]Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, Kanehira T, Yamamoto S, Kondo T, Endo T, Tanaka J, Hashino S, Nishio M, Imamura M, Kitagawa Y, Inoue N: Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation. Support Care Cancer 2012, 20:367-373.
• [3]Greenberg MS, Cohen SG, McKitrick JC, Cassileth PA: The oral flora as a source of septicemia in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 1982, 53:32-36.
• [4]Meurman JH, Pyrhönen S, Teerenhovi L, Lindqvist C: Oral sources of septicaemia in patients with malignancies. Oral Oncol 1997, 33:389-397.
• [5]National Institutes of Health Consensus: Development panel Consensus statement: oral complications of cancer therapy. NCI Monogr 1990, 9:3-8.
• [6]Peterson DE: Pretreatment strategies for infection prevention in chemotherapy patients. NCI Monogr 1990, 9:61-71.
• [7]Elad S, Thierer T, Bitan M, Shapira MY, Meyerowitz C: A decision analysis: the dental management of patients prior to hematology cytotoxic therapy or hematopoietic stem cell transplantation. Oral Oncol 2008, 44:37-42.
• [8]Barasch A, Mosier KM, D'Ambrosio JA, Giniger MS, Ascensao J, Peterson DE: Postextraction osteomyelitis in a bone marrow transplant recipient. Oral Surg Oral Med Oral Pathol 1993, 75:391-396.
• [9]Overholser CD, Peterson DE, Bergman SA, Williams LT: Dental extractions in patients with acute nonlymphocytic leukemia. J Oral Maxillofac Surg 1982, 40:296-298.
• [10]Tai CC, Precious DS, Wood RE: Prophylactic extraction of third molars in cancer patients. Oral Surg Oral Med Oral Pathol 1994, 78:151-155.
• [11]Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, Conference ISD: SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2001, 2003(29):530-538.
• [12]Sonis S, Kunz A: Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surg Oral Med Oral Pathol 1988, 65:19-22.
• [13]Elad S, Garfunkel AA, Or R, Michaeli E, Shapira MY, Galili D: Time limitations and the challenge of providing infection-preventing dental care to hematopoietic stem-cell transplantation patients. Support Care Cancer 2003, 11:674-677.
• [14]Miller CS, Epstein JB, Hall EH, Sirois D: Changing oral care needs in the United States: the continuing need for oral medicine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001, 91:34-44.
• [15]Woo SB, Matin K: Off-site dental evaluation program for prospective bone marrow transplant recipients. J Am Dent Assoc 1997, 128:189-193.
• [16]Yamagata K, Onizawa K, Yanagawa T, Takeuchi Y, Hasegawa Y, Chiba S, Bukawa H: Prospective study establishing a management plan for impacted third molar in patients undergoing hematopoietic stem cell transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 111:146-52.
• [17]Raber-Durlacher JE, Epstein JB, Raber J, van Dissel JT, van Winkelhoff AJ, Guiot HF, van der Velden U: Periodontal infection in cancer patients treated with high-dose chemotherapy. Support Care Cancer 2002, 10:466-473.
• [18]Soga Y, Yamasuji Y, Kudo C, Matsuura-Yoshimoto K, Yamabe K, Sugiura Y, Maeda Y, Ishimaru F, Tanimoto M, Nishimura F, Takashiba S: Febrile neutropenia and periodontitis: lessons from a case periodontal treatment in the intervals between chemotherapy cycles for leukemia reduced febrile neutropenia. Support Care Cancer 2009, 17:581-587.
• [19]Yamagata K, Onizawa K, Yanagawa T, Hasegawa Y, Kojima H, Nagasawa T, Yoshida H: A prospective study to evaluate a new dental management protocol before hematopoietic stem cell transplantation. Bone Marrow Transplant 2006, 38:237-242.
• [20]Soga Y, Sugiura Y, Takahashi K, Nishimoto H, Maeda Y, Tanimoto M, Takashiba S: Progress of oral care and reduction of oral mucositis–a pilot study in a hematopoietic stem cell transplantation ward. Support Care Cancer 2010, 19:303-307.
• [21]Raber-Durlacher JE, Laheij AM, Epstein JB, Epstein M, Geerligs GM, Wolffe GN, Blijlevens NM, Donnelly JP: Periodontal status and bacteremia with oral viridans streptococci and coagulase negative staphylococci in allogeneic hematopoietic stem cell transplantation recipients: a prospective observational study. Support Care Cancer 2013, 21:1621-1627.